INCR

InterCure Ltd.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

InterCure Ltd. (INCR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (C+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.6
EV / EBITDA N/A
Rev Growth YoY 23.9%
Gross Margin 15.1%
Price Return 3M -15.6%
Price Return 12M -45.3%
Catalyst Signal 0.00
Market Cap $50.7M
TTM Revenue N/A
Price / Sales N/A
ROE -9.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C+ (2.7) C+ (2.8) B- (3.0) C+ (2.6) C+ (2.7)
2026-11-05 C+ (2.5) B- (2.9) C+ (2.7) C+ (2.8) C+ (2.7) C+ (2.7)
2026-10-29 C+ (2.5) C+ (2.8) C+ (2.8) B- (3.0) C+ (2.7) C+ (2.7)
2026-10-22 C+ (2.5) C+ (2.8) C+ (2.8) B- (2.9) C+ (2.6) C+ (2.7)
2026-10-15 C+ (2.5) C+ (2.8) C+ (2.8) B- (3.1) C+ (2.6) C+ (2.8)
Page 1 of 4